Forecasting Failures from Wall Street Gurus, Economists & Leading Financial Institutions

GLASTONBURY, CT / ACCESSWIRE / February 19, 2020 / Symmetry Partners, LLC has just released its list of the 10 Worst Financial & Economic Predictions of 2019.

Forecasting short-term trends is notoriously difficult, yet every year Wall Street gurus, economists, and leading financial institutions try to predict what they believe will happen in global markets over the next twelve months. Sometimes they get it right. But more often than not, they don't. And sometimes they make spectacularly bad calls.

Symmetry Partners List of 10 Worst Financial & Economic Predictions of 2019

Symmetry's 2019 list features a number of prominent Wall Street Firms that missed the mark, including Charles Schwab, Morgan Stanley, Capital Group and Russell Investments. Failed predictions include bear markets that didn't occur, stocks that didn't outperform, and Federal Reserve rate increases that didn't happen.

According to J. William G. Chettle, Director of Experience & Engagement with Symmetry Partners, "Market forecasts are almost by definition inaccurate, as markets are affected by a broad range of unpredictable variables. The global economy, geopolitical events, domestic politics, monetary policy and interest rates all factor in, and we can never overlook the role of human emotion and investor sentiment. We view any attempt to predict short-term market movements and trends with considerable skepticism."

While billions of dollars are potentially wasted following flawed advice, there is a larger opportunity cost when investors are distracted or diverted from following their long-term plans.

As Patrick Sweeny, Symmetry's Principal and Co-Founder, notes, "Because we believe in the long-term potential of markets to reward investors, we favor an investment approach built on logic, empirical evidence, and academic research. Investing for the long-term and sticking to a well-defined strategy is, in our opinion, the best way for investors to achieve their financial goals."

About Symmetry Partners

Founded in 1994, Symmetry Partners provides financial advisors with a complete business solution. This includes best-of-breed, evidence-based investments, including the firm's own family of mutual funds, as well as marketing, technology and operational assistance to help Advisors more effectively serve their clients.

As of December 31, 2019, Symmetry Partners has $8.4 billion in assets under management and assets under advisement, where Symmetry acts as a sub-advisor. For more information, please visit www.symmetrypartners.com.

Media Contact:

J. William G. Chettle
​​wchettle@symmetrypartners.com
860.500.3502

Symmetry Partners, LLC is a Registered Investment Advisor located in Glastonbury, Connecticut. The firm designs and manages portfolios made available through a group of select advisors, including a suite of factor-based mutual fund and ETF portfolios. This content should not be considered investment advice. Information is provided for educational and background use only.

SOURCE: Symmetry Partners

ReleaseID: 576917

Traveling is such an amazing way to experience all the wondrous views and sites that the world has to offer. Whether it be done with friends, or just by flying solo, traveling fills the mind with new stories, new friends, and new memories that will stay with you forever. flyBARBARA, a Czech startup built with an intention to fulfill travelers' dreams, shows their commitment to protect the environment by announcing plans to plant trees to compensate for the CO2 produced by air traffic

PILSEN, CZECH REPUBLIC / ACCESSWIRE / February 19, 2020 / Traveling lets you meet new people whether it be on the plane, sitting next to someone who could potentially be your next new adventure. People have met from all over the world just from meeting in a new location. There's nothing better than knowing that there are people out there just like you with a thirst for adventure and have the same aspirations as you do. Popular travel platform, flyBARBARA gives its customers an opportunity to be a part of their initiative to preserve the eco-system, by committing one-third of the profit to plant trees.

flyBARBARA is an all in one travel company that serves its clients by allowing them to book everything from the flight, hotel, and everything in between. Simply select the airport you want to fly out of, into and the date in which your dream vacation is planned for. From the roofs of Saint Petersburg to the lush green fields of Vietnam, people are able to experience their dream destinations thanks to flyBARBARA doing all the travel planning for them. The team behind the platform believes sharing travel photos is the best way to inspire others to create their own memorable travel experience. From leading their customers down the safest paths through remote or bustling areas, flyBARBARA aims to provide travelers with the resources to help them manage time and find the most fascinating areas to visit with every precious moment inside one's dream destination.

"We started the project to simplify traveling for everyone by providing all the necessary information a traveler would want without the hassle of going through so many platforms. But we wanted to do more, that's why we are committing one-third of our profit to plant trees to compensate with the CO2 emission from the air traffic." explains CEO Josef Pavelec.

The fact that flyBARBARA wants to renounce one-third of their profit to help the eco-system sustain its balance makes them a fine example to other similar platforms and transforms them into a truly unique startup. Their goal is to help reduce the carbon footprint while letting others create their own footprints across the world. The travel startup country donates a portion of its profits in order to combat the effects of excessive carbon emissions in the air from airplanes. flyBARBARA's decision to plant new trees will release more oxygen, eating up the offsetting amount of carbon dioxide being released into the air. Not only are they working towards filling in the forests devoid of plant life, but they are completely transparent in all of their efforts to make the world green again.

The company wants to keep everything transparent and all the records from donations, trees planted, and the number of tickets sold can be seen on a monthly basis on their website. Planes can release toxins that harm the environment, but flyBARBARA makes it their mission to make travel as safe and as frequent as possible for the next round of future explorers. More details about the platform can be found at https://www.flyBARBARA.com

Media contact information
Name: David Vejvancicky
Company: flyBARBARA
Email: info@flybarbara.com
Website: https://www.flyBARBARA.com

SOURCE: flyBARBARA

ReleaseID: 576961

In-depth method comparison by Dutch group shows that sphingotec's proprietary kidney function biomarker penKid(R) is currently the most accurate surrogate marker for true glomerular filtration rate in patients with renal impairment
Data by PRONOBURNS group show that penKid(R) accurately predicts acute kidney injury (AKI) in patients with burns, adding benefit on top of standard testing
Since January 2020, an automated CE-marked IVD penKid(R) assay developed for sphingotec's proprietary point-of-care platform Nexus IB10 is available for use in critical care settings

HENNIGSDORF and BERLIN, GERMANY / ACCESSWIRE / February 19, 2020 / Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf Germany) today announced the publication of two studies demonstrating that its kidney function biomarker Proenkephalin (penKid(R)) is the most accurate surrogate for assessing true glomerular filtration rate (true GFR) and is reliably predictive for acute kidney injury (AKI) in patients with severe burns. Although AKI is a major complication in critically ill patients, current diagnostic standard methods do not properly and timely diagnose impaired renal function. The two recently published studies add to the rapidly growing body of evidence suggesting that penKid(R) can address this highly unmet diagnostic need.

In Shock1, a team headed by Prof. Peter Pickkers from Radboud UMC (Nijmegen, The Netherlands) confirmed by in-depth diagnostic method comparison in patients with impaired kidney function that penKid(R) levels properly reflect kidney function. While today's standard of care uses estimations of the glomerular filtration rate (eGFR) to assess renal impairment, the current study shows that these methods overestimate true GFR with over 30%. The published findings demonstrate that penKid(R) can add value by properly reflecting true GFR that can otherwise only be measured using in vivo clearance of iohexol, an invasive method too laborious and time-consuming for clinical routine use.

Another study published in the Journal of Burns2 reports for the first time that high penKid(R) plasma levels at admission to the intensive care unit (ICU) were associated with the risk for developing AKI in patients with severe burns, where mortality rates range from 30-70%.

The new data suggest, that the current renal function- and AKI standard markers should be complemented with penKid(R) values for accurately quantifying the kidney function in critically ill patients. Dr. Andreas Bergmann, CEO of sphingotec, commented: "penKid(R) is an early renal function biomarker that is not biased by co-morbidities while reflecting true GFR. penKid(R) has been tested for the first time to identify ICU patients with severe burns that need rapid and aggressive intervention to prevent mortality caused by AKI."

To support timely treatment decisions that are likely to improve patient management in critical care patients, sphingotec launched a fully automated CE-IVD-marked penKid(R) assay on its Nexus IB10 platform in January 2020. This new test complements a wide-range of assays for acute care settings that are already available on this widely used point-of-care platform that can be flexibly deployed in near-patient as well as laboratory settings.

Beunders, R. et al., Proenkephalin compared to conventional methods to assess kidney function in critically ill sepsis patients, Shock,, doi:10.1097/SHK.0000000000001510
Depret, F. et al, PenKid measurement at admission is associated with outcome in severely ill burn patients, J.Burns, doi: doi.org/10.1016/j.burns.2020.01.002

About sphingotec 
 SphingoTec GmbH ("sphingotec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies. sphingotec's proprietary biomarker portfolio includes Bioactive Adrenomedullin (bio-ADM(R)), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid(R)), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardio-renal pathway disruptions leading to acute organ dysfunction. In addition, sphingotec develops a portfolio of novel biomarkers, which predict the risks of developing obesity, breast cancer and cardiovascular diseases. IVD tests for sphingotec's proprietary biomarkers are made available as sphingotest(R) microtiterplate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by sphingotec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of IB10 tests for established biomarkers for acute and critical care.

About penKid(R)
sphingotest(R) penKid(R) measures proenkephalin (penKid(R)), a stable fragment of the kidney stimulating hormone enkephalin. penKid(R) has been demonstrated to be a real-time surrogate biomarker for glomerular filtration rate, the gold standard to assess renal function. Measuring penKid(R) blood concentrations allows for timely information on kidney function in critically ill patients. Early assessment of worsening and improving of renal function on intensive care units and in emergency departments allows adjustment of nephrotoxic drug administration and the initiation of kidney-protective strategies to prevent acute kidney injury and thereby improve outcomes.

About Nexus Dx Inc. and the IB10 Platform 
Nexus Dx Inc., a wholly-owned subsidiary of sphingotec, headquartered in San Diego, CA, USA, is a global provider of a near patient testing system and advanced diagnostic solution. The company is improving patient care by providing the medical community with rapid and reliable information at the point of care (POC), delivering patient information when and where it is needed most. The company has invested over $160m to develop and market the IB10 analyzer system which, without the need for sample preparation, automatically separates plasma from whole blood with subsequent reliable and quantitative detection of biomarkers in the plasma by means of antibodies. With a hands-on-time of less than 3 minutes the easy-to-use system provides in only 20 minutes test results for biomarkers that are crucial in the management of critical care patients. The portfolio of IB10 assays includes tests for established critical care parameters such as Procalcitonin, Troponin I, CK-MB, Myoglobin, NT-proBNP, and D-Dimer as well as tests for sphingotec's proprietary biomarkers such as DPP3, an assay for Dipeptidyl Peptidase 3, a unique and proprietary biomarker for cardio-renal pathway disruptions leading to acute organ dysfunction, and Proenkephalin (penKid(R)), a unique and proprietary biomarker for real-time assessment of kidney function. An IB10 assay for bioactive Adrenomedullin (bio-ADM(R)), a unique and proprietary biomarker for endothelial function is expected to be launched later in 2020. 

Contact 
SphingoTec GmbH
Ruxandra Lenz
Neuendorfstr. 15a
16761 Hennigsdorf
Germany
Tel. +49-3302-20565-0
press@sphingotec.de
www.sphingotec.com
 
SOURCE: SphingoTec GmbH via EQS Newswire

ReleaseID: 576958

Highlighting Larazotide's Effect across the Gut-Vascular Barrier – a Fundamental Disease Mechanism in a Variety of Autoimmune and Inflammatory Diseases

RALEIGH, NC / ACCESSWIRE / February 19, 2020 /  Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT), a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, announced that three abstracts were accepted for poster presentations during the 2020 Digestive Disease Week (DDW) conference being held May 2-5, 2020, in Chicago, IL. These abstracts, separately authored with University of Maryland and North Carolina State University, continue to show larazotide's ability to reduce permeability in various in-vitro models and to develop further understanding of tight junction regulation. These data further add to the accumulating body of knowledge on the complexity, selectivity and dynamic character of the intestinal epithelial barrier. Combining this evidence with the totality of work to date with larazotide, a consistent picture of restoring epithelial integrity is emerging, which could be further explored in patients with a variety of diseases involving antigen and bacterial end product trafficking across the gut-vascular barrier.

Title: EXPLORING THE MECHANISMS OF LARAZOTIDE IN THE REGULATION OF THE TIGHT JUNCTION BARRIER (Abstract # 3348407)

Date/Time: Saturday, May 2, 2020, from 12:30pm – 1:30pm CT
Poster Session Title: Epithelial Junctions and Barrier Function

Title: CHIRALLY-MODIFIED LARAZOTIDE COMPOUND ANALOG #6 FACILITATES RECOVERY OF ISCHEMIC-INJURED PORCINE JEJUNUM VIA RE-ASSEMBLY OF INTRAEPITHELIAL TIGHT JUNCTIONS (Abstract # 3353776)

Date/Time: May 5, 2020, from 12:30pm – 1:30pm CT
Poster Session Title: Molecular Mechanisms of Disease: Genetics, Signaling

Title: IN-VIVO ASSESSMENT OF CELIAC CLINICAL FORMULATION OF LARAZOTIDE IN THE PORCINE GASTROINTESTINAL TRACT USING A NOVEL ULTRAFILTRATION MODEL (Abstract # 3348457)

Date/Time: May 5, 2020, from 12:30pm – 1:30pm CT
Poster Session Title: Celiac Disease and Gluten Related Disorders Pathogenesis

Executive Chairman of Innovate, Sandeep Laumas, M.D., stated, "Targeting the restoration of the gut-vascular barrier is an emerging field with exciting data from GI diseases, oncology and neurodegenerative diseases. Further data elucidating the mechanism of action and novel formulations of larazotide such as the development of chirally different larazotide molecules helps us address larazotide's pharmacology and bring the next generation of tight junction regulators for the treatment of autoimmune and inflammatory diseases."

"This exciting new work from our collaboration with Innovate is revealing not only novel mechanisms by which larazotide repairs interepithelial tight junctions in injured, or leaky, intestines, but also how to pharmaceutically ensure optimal stability of the peptide therapeutic within the intestine," remarked Anthony Blikslager, DVM, PhD, DACVS, AGAF, Professor of Equine Surgery and Gastroenterology at NC State University's College of Veterinary Medicine.

About Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT):

Innovate is a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases. Innovate's lead drug candidate, larazotide acetate, has a mechanism of action that renormalizes the dysfunctional intestinal barrier by decreasing intestinal permeability and reducing antigen trafficking, such as gliadin fragments in celiac disease, and bacterial toxins and immunogenic antigens in nonalcoholic steatohepatitis (NASH). In several diseases, including celiac disease, NASH, ASH, Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS), type 1 diabetes mellitus (T1DM), chronic kidney disease (CKD), the intestinal barrier is dysfunctional with increased permeability. On October 7, 2019, the Company announced that it had entered into a definitive merger agreement pursuant to which the Company agreed to acquire all of the outstanding capital stock of privately held RDD in an all-stock transaction. This transaction includes a concurrent capital raise led by OrbiMed Advisors LLC. After closing the Company will change its name to 9 Meters Biopharma. The transaction is expected to close in the beginning of the second quarter of 2020, subject to the completion of the remaining closing conditions and receipt of regulatory approval in Israel.

For more information, please visit www.innovatebiopharma.com.

Forward-Looking Statements

This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials; the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, as well as the risks that prior clinical and preclinical results may not be replicated; the lengthy and unpredictable nature of the drug approval process; and our ability to commercialize our product candidates if approved. These risks and uncertainties include, but may not be limited to, those described in our Annual Report on Form 10-K for the year ended December 31, 2018, and Quarterly Report on Form 10-Q and in any subsequent filings with the SEC. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

Contact:

Jennifer K. Zimmons, Ph.D.
Investor Relations
Tel: +1-917-214-3514
Email: jzimmons@innovatebiopharma.com
www.innovatebiopharma.com

SOURCE: Innovate Biopharmaceuticals, Inc

ReleaseID: 576943

NIAGARA FALLS, ONTARIO / ACCESSWIRE / February 19, 2020 / EnerDynamic Hybrid Technologies Corp. (TSXV:EHT) ("EHT") is pleased to provide an update on its Ghana UNOPS Solar Contract.

As we previously announced, we scheduled a meeting on our last trip to Ghana with SHS Sustainable Housing ("SHS"), which is partnered with the UNOPS for the 100,000-housing project in Ghana. At the meeting with the SHS Director, we discussed the contract we have with the Ministry of Housing and our Enertec Solar Solution that will be utilized and the benefit thereof to SHS.

While the UNOPS project is running about 8 months behind schedule, since the first site chosen did not meet all the requirements and a new site had to be secured, both SHS and EHT agreed that now is the time to initiate the process to have EHT be officially included on the SHS project list of suppliers. Since EHT CEO's return from Ghana, we have now assembled and filed all the documents required by the UNOPS program with SHS for EHT to become a supplier to the project and receive all the final drawings required to supply the ENERTEC Solar System thereto.

We anticipate we will have all the requisite housing drawings etc. in the next few weeks and will then be in a position to move forward with the contract to start the necessary supply in Q4 of 2020. We will continue to update the market as we move forward with this order.

The UNOPS order is part of the Government of Ghana's Building of Social Green Housing initiative that is at the forefront of the Government's Solar program and one of its priority governmental infrastructure projects.

John Gamble, CEO of EHT, commented that "We are pleased to move this project ahead, as we know projects in other countries take longer than originally planned. EHT is well positioned now in Ghana to move ahead with this and our other projects and will continue to look for other opportunities there as they present themselves."

About EnerDynamic Hybrid Technologies

EHT delivers proprietary, turn-key energy solutions which are intelligent, bankable and sustainable. EHT's expertise includes the development of its ENERTEC module structures with full integration of smart energy solutions. Using a proprietary skin and foam core that is stronger than traditional wood or steel structural insulated panels, EHT provides exceptional thermal energy efficiency in modular homes, cold storage facilities, residential/commercial out buildings and emergency/temporary shelters. EHT works with its partners worldwide to erect the buildings on-site utilizing EHT staff and local crews. In addition to traditional support to established electrical networks, ENERTEC buildings excel where no electrical grid exists.

About ENERTEC

The EHT advanced ENERTEC Modular Wall and Roof System uses a proprietary skin and foam core that is stronger and more energy efficient than traditional wood or steel structures providing the highest ratings for energy efficiency. EHT works with its partners worldwide to erect the buildings on-site utilizing EHT staff and local crews. After installation, each structure can be furnished and finished to meet the customer's requirements including siding, tile, kitchens and bathrooms or segregated commercial rooms. The finished wall product can be shipped on pallets and delivered via rail, truck or water in standard formats.

At the core of the ENERTEC product line is the ENERTEC Embedded Solar Roof Module. Solar cells can be embedded in a proprietary fire proof skin resulting in substantial cost savings by eliminating heavy glass panels and aluminum racking required for traditional solar panels. Two barriers to greater adoption of solar energy are weight limitations of the roof on which solar panels could be deployed and onerous shipping and labour costs. A lighter product at a better price point will open a larger market for solar due to the faster return of capital investment especially for rural and remote users looking to go off-grid. Furthermore, the entire EHT embedded solar roof becomes a massive solar panel capable of producing significantly more energy than the home requires, allowing the structure to then become an important source of power for the local micro grid or large battery storage systems.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The statements herein that are not historical facts are forward‐looking statements. Forward-looking information relating to sales of the products (the "Opportunities") involves risk, uncertainties and other factors that could cause actual events, results, performance, prospects, for the Opportunities to differ materially from those expressed or implied by such forward-looking information. Although EHT believes that the assumptions used in preparing the forward-looking information on the Opportunities outlined in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. EHT disclaims any intention or obligation to update or revise any forward-looking information, whether a result of new information, future events or otherwise, other than as required by applicable securities laws.

FOR FURTHER INFORMATION PLEASE CONTACT:

John Gamble
Director
(289) 488-1699
jgamble@ehthybrid.com
info@ehthybrid.com
Website: www.ehthybrid.com

SOURCE: EnerDynamic Hybrid Technologies Corp.

ReleaseID: 576929

No-Code Machine Learning Platform makes data science effortless by enabling anyone to run predictions and analytics using natural language questions

BERKELEY, CA / ACCESSWIRE / February 19, 2020 / Data at organizations can be incredibly siloed, difficult to access, and overwhelming for thousands of business users across the globe. From finding a list of items in a haystack of data, to running complex predictive analytics, business users often have to wait for weeks for data engineers to get a single question answered. Today, with the public launch of Obviously AI, a no-code platform designed to put the power of machine learning and analytics in the hands of non-technical business users, this solution can enable anyone to access crucial information and data predictions, simply by asking questions in natural language.

Obviously AI's no-code tool is extremely easy to use with results on any query returned in under a minute. Users simply upload their dataset from CSV, databases or CRMs and then get a Google-like search bar to ask a question in natural language. For predictive questions, such as "Which customers are likely to cancel their subscriptions?" the platform will understand what the user is asking, find the right data, and build a machine learning algorithm on the fly. It also shows you exactly what factors drove your results, so you don't have to guess how it got them. Similarly, the platform can answer analytical questions that look for existing patterns in data, such as "What is the average daily foot traffic for my retail stores?" Users do not need any familiarity with writing complex SQL queries or working with programming languages to code regressions, neural networks and other ML algorithms.

"We realized that business users truly cared about getting decision making insights about their customers, products and its usage. This often meant writing frustrating SQL queries and waiting on web engineers who would try to figure out machine learning algorithms," said Nirman Dave, Co-founder and CEO, Obviously AI. "That's why we have been on a mission to make data science effortless just by asking questions. It's amazing what marketers, salespeople and other non-technical business users can learn when they use our platform."

How it works

To make predictions, Obviously AI uses state-of-the-art natural language processing to break apart a question, interpret it and find the right data. Then it runs hundreds of machine learning algorithms in parallel and evaluates each one for accuracy to find the right algorithm for your dataset. Finally, it identifies top attributes that impact the outcome you are trying to predict and delivers highly accurate reports in under a minute.

Here are the sorts of straight-forward yet vitally important questions Obviously AI can address:

Which users are most likely to make an in-app purchase?
How much is a customer willing to pay for my product on Wednesdays?
Which customers are most likely to commit fraudulent activity in February?
Will Tim Smith miss his appointment today?
Which users are likely to buy again?
Age and location of user paying more than $500?

Analytics is equally simple: input your dataset, and ask a natural language question such as "What's the average income from customers in cities in California?" Obviously AI will understand the question, find the right data and visualize it in a beautiful graph. Outputs can be exported into presentations or more closely analyzed.

"The predictions come faster than any other tools – literally in less than a minute and with incredible accuracy," said Dave.

The platform is ideal for a range of small and medium businesses or small departments of larger companies that don't have a data science team or cannot scale one. For example, in marketing the software can predict churn, lifetime value and returning customers. For SaaS companies, it can assist in predicting conversion KPIs and in-app purchases. Even in traditionally non-technical markets like retail, the software can optimize assortments, predict inventory burn and forecast staffing. Similarly, for healthcare companies it can assist administrators to predict and prevent hospital readmissions, predict which patients are less likely to adhere to prescribed drug regimens and as well as help predict appointment no-shows.

Other use cases include insurance, banking and gaming.

All the user needs to get started is a CSV file and a question they want to ask. The platform is available in Free, Pro and Pro Plus versions.

Videos

How it Works – Predictions Demo: https://www.youtube.com/watch?v=d_1pzpzEP6I
How it Works – Analytics Demo: https://www.youtube.com/watch?v=XnOCxwfwEvc
Trailer: https://www.youtube.com/watch?v=LBe03gGLuRk

Images https://drive.google.com/drive/folders/1ahMK6YzYEwYtuU3Tk2x8YWb_jxoiiXve

About Obviously AI

Obviously AI was founded on the belief that business users should be able to get insights from their data, without waiting on an engineer. Our mission is to make data science effortless by enabling anyone to run complex data predictions and analytics, simply by asking questions in natural language with no code, no hassle and no waiting. It is the only platform to use simple Natural Language questions for data prediction, delivering predictions and analytics in less than a minute. For more information, visit obviously.ai.

Media Contact:
Erica Zeidenberg
erica@hottomato.net
925-518-8159 mobile
925-631-0553 office

SOURCE: Obviously AI

ReleaseID: 576953

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO

DIDCOT, UK / ACCESSWIRE / February 19, 2020 / Altus Strategies Plc (AIM:ALS)(TSX-V:ALTS), the Africa focused project and royalty generator, announces that at its general meeting ("General Meeting") held on 18 February 2020, the shareholders of the Company ("Shareholders") approved all resolutions to effect the proposed strategic investment ("La Mancha Strategic Investment") by La Mancha Holding S.à r.l. ("La Mancha") in the Company and a five to one consolidation of the Company's share capital ("Share Consolidation"). The issue of 124,229,389 new ordinary shares ("Ordinary Shares") in the Company at a price of C$0.09 per Ordinary Share, to La Mancha is conditional upon Admission. Completion of the La Mancha Strategic Investment ("Completion") will only remain conditional upon the receipt by the Company of C$11,180,645 ("Subscription Price") (approximately £6.5 million), Admission (as defined below) and receipt of regulatory approval of the TSX Venture Exchange ("TSX-V"). Admission and Completion are expected to take place on 21 February 2020.

Highlights:

Conditional strategic investment by La Mancha of approximately C$11.2 million (approximately £6.5 million / approximately US$8.4 million) approved by Altus shareholders
Transformational deal to accelerate the Company's project and royalty strategies in Africa
On Completion:

La Mancha will become a cornerstone shareholder owning approximately 35.4% of the then enlarged share capital of Altus
La Mancha will have the ability to appoint two representatives to the Altus' board of directors

Following Completion the Altus treasury of cash and listed equities will be approximately C$18.2M / £10.5M
Five into one share consolidation to be undertaken effective as at the close of trading on 21 February 2020

Steven Poulton, Chief Executive of Altus, commented:

"We are delighted that our shareholders have overwhelmingly approved the strategic investment by La Mancha, a pre-eminent Africa-focused mining investment group with a notable track record in deal selection and value creation. The directors believe that this transaction will be transformative for Altus, providing the capital and expertise to fast track our project and royalty generation activities, as well as unlocking new external growth opportunities. The directors are of the view that the deal also represents a strong industry endorsement of the Altus team, portfolio and business model. We thank our shareholders for their continued support and look forward to keeping them advised of our progress."

La Mancha Strategic Investment

Upon the receipt of the subscription price and final TSX-V approval, the Company will issue to La Mancha 124,229,389 new Ordinary Shares in the Company at a price of C$0.09 per Ordinary Share, for aggregate gross proceeds of C$11,180,645 (approximately £6.5m / US$8.4m). On Admission, La Mancha will own approximately 35.4 per cent. of the enlarged share capital of the Company. The Company will make a further announcement in relation to Completion and the subsequent Share Consolidation.

Pursuant to the Strategic Investment Agreement, La Mancha has agreed (subject to certain customary exceptions) not to dispose of any its shares in the Company for a period of 24 months following Admission. No finder fees or other commissions are being paid in respect of the La Mancha Strategic Investment.

Rule 9 Waiver

Without a waiver of the obligations under Rule 9 of the UK City Code on Takeovers and Mergers (commonly referred to as a "Whitewash"), the La Mancha Strategic Investment would require La Mancha (and any persons acting in concert with it) to make a general offer for the entire issued and to be issued share capital of the Company not already held by La Mancha (and any persons acting in concert with it). The Resolution relating to the Whitewash was approved on a poll by independent shareholders at the General Meeting on 18 February 2020. Since the La Mancha Strategic Investment will result in La Mancha owning more than 20 per cent. of the total voting rights of the Company and thereby becoming a "control person" under TSX-V policies, the issue of Ordinary Shares to La Mancha was also conditional on the approval of disinterested shareholders at the General Meeting.

Share Consolidation

As approved by Shareholders at the General Meeting, the Company will undertake the Share Consolidation, by way of one consolidated ordinary share ("Consolidated Ordinary Share") for every five existing Ordinary Shares. It is expected that the Share Consolidation will be effective after the close of trading in the Company's shares on AIM and TSX-V on 21 February 2020 (the "Share Consolidation Record Date").

Most Shareholders will not hold at the Share Consolidation Record Date a number of Ordinary Shares that is exactly divisible by the consolidation ratio. The result of the Share Consolidation, will be that such Shareholders will be left with fractional entitlement to a resulting Consolidated Ordinary Share. However, no fractional Ordinary Shares will be issued upon effecting the Share Consolidation. If, as a result of the Share Consolidation, a holder of existing Ordinary Shares would otherwise be entitled to a fraction of a Consolidated Ordinary Share, such fraction shall be rounded up to one whole Consolidated Ordinary Share. The nominal value of the new Consolidated Ordinary Shares to be issued in order to round up any fractional entitlement will be paid up from the Company's share premium account as fully-paid bonus shares. As a result of the Share Consolidation, there will be certain proportional adjustments to outstanding warrants to acquire Ordinary Shares to preserve the rights of holders of such securities to the relevant proportion of Consolidated Ordinary Shares.

As a result of the Share Consolidation the Company will have approximately 70,091,570 issued and outstanding Consolidated Ordinary Shares. The Company will make a further announcement in respect of the number of shares in issue as a result of fractional shares being rounded up following the Share Consolidation.

Admission of Ordinary Shares to AIM

Application has been made for the 124,229,389 new Ordinary Shares issued under the La Mancha Strategic Investment to begin trading on AIM and it is expected that admission and dealings in the new Ordinary Shares will commence on AIM ("Admission") at 8.00 a.m. on, or around, 21 February 2020.

Total Voting Rights

Following the La Mancha Strategic Investment and prior to the Share Consolidation, there will be a total of 350,457,850 issued Ordinary Shares, none of which are held in treasury. Shareholders should use that number as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

No offer or solicitation

This Announcement is for information purposes only and does not constitute an invitation to any person to purchase or subscribe for Ordinary Shares or any other securities or engage in any form of investment activity. This Announcement is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or within the United States of America its territories and possessions, any state of the United States or the District of Columbia (collectively, the "United States"), Australia, Japan, New Zealand or the Republic of South Africa or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction. This Announcement is also being released in Canada as part of the Company' continuous disclosure record.

This Announcement is directed only at persons in member states of the European Economic Area ("EEA") and the United Kingdom who are qualified investors within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended from time to time (the "Prospectus Regulation"), ("Qualified Investors"). In addition, in the United Kingdom, this Announcement and any offer if made subsequently is directed only at Qualified Investors, who are also (i) persons who have professional experience in matters relating to investments falling within the definition of "Investment Professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (ii) high net worth entities falling within Article 49(2) of the Order or (iii) other persons to whom it may lawfully be communicated (all such persons together being referred to as "Relevant Persons"). This Announcement must not be acted on or relied on (i) in any member state of the European Economic Area, by any person who is not a Qualified Investor (ii) in the UK, by any person who is not a Qualified Investor and a Relevant Person.

For further information you are invited to visit the Company's website www.altus-strategies.com or contact:

Altus Strategies Plc
Steven Poulton, Chief Executive
Tel: +44 (0) 1235 511 767
E: info@altus-strategies.com

SP Angel (Nominated Adviser)
Richard Morrison / Soltan Tagiev
Tel: +44 (0) 20 3470 0470

SP Angel (Broker)
Abigail Wayne / Richard Parlons
Tel: +44 (0) 20 3470 0471

Blytheweigh (Financial PR)
Tim Blythe / Camilla Horsfall
Tel: +44 (0) 20 7138 3204

About Altus Strategies Plc

Altus is a London (AIM: ALS) and Toronto (TSX-V: ALTS) listed project and royalty generator in the mining sector with a focus on Africa. Our team creates value by making mineral discoveries across multiple licences. We enter joint ventures with respected groups and our partners earn interest in these discoveries by advancing them toward production. Project milestone payments we receive are reinvested to extend our portfolio, accelerating our growth. The portfolio model reduces risk as our interests are diversified by commodity and by country. The royalties generated from our portfolio of projects are designed to yield sustainable long-term income. We engage constructively with all our stakeholders, working diligently to minimise our environmental impact and to promote positive economic and social outcomes in the communities where we operate.

Cautionary Note Regarding Forward-Looking Statements

Certain information included in this Announcement, including information relating to future financial or operating performance and other statements that express the expectations of the Directors or estimates of future performance constitute "forward-looking statements". These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include without limitation the completion of the La Mancha Strategic Investment, admission of the Ordinary Shares to AIM and the receipt of final TSX-V approval, planned expenditures, the ability to complete exploration programmes on schedule and the success of exploration programmes. Readers are cautioned not to place undue reliance on the forward-looking information, which speak only as of the date of this Announcement and the forward-looking statements contained in this announcement are expressly qualified in their entirety by this cautionary statement.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. The forward-looking statements contained in this Announcement are made as at the date hereof and the Company assumes no obligation to publicly update or revise any forward-looking information or any forward-looking statements contained in any other announcements whether as a result of new information, future events or otherwise, except as required under applicable law or regulations.

Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

Market Abuse Regulation Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR") until the release of this announcement.

Disclaimer
SP Angel Corporate Finance LLP, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for the Company and no one else (including the recipients of this announcement) as nominated adviser and will not be responsible to anyone other than the Company for providing the protections afforded to customers of SP Angel Corporate Finance LLP or for advising any other person in relation to the matters described in this announcement.

Capitalised terms

Capitalised terms used but not defined in this announcement have the meanings set out in the circular dated of 14 January 2020.

Exchange Rates

Exchange rates in this announcement are based on a C$/£ exchange rate of C$1:£ 0.57858 and a C$/US$ exchange rate of C$1:US$ 0.75474.

SOURCE: Altus Strategies PLC

ReleaseID: 576926

NEW YORK, NY / ACCESSWIRE / February 19, 2020 / Blue Apron Holdings, Inc. (NYSE:APRN) will be discussing their earnings results in their 2019 Fourth Quarter and Fiscal Year Financial Results call to be held on February 19, 2020 at 8:30 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/event/presentation/58306

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 576885

NEW YORK, NY / ACCESSWIRE / February 19, 2020 / Navios Maritime Holdings, Inc. (NYSE:NM) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 19, 2020 at 8:30 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/event/presentation/59488

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 576890

NEW YORK, NY / ACCESSWIRE / February 19, 2020 / Fiverr International Ltd (NYSE:FVRR) will be discussing their earnings results in their 2019 Fourth Quarter and Full Year Results call to be held on February 19, 2020 at 8:30 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/event/presentation/58302

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 576889